Merz Pharma GmbH & Co KGaA - Headquarters
Eckenheimer Landstraße 100
60318 Frankfurt am Main


Production and manufacturing at Dessau since 2002

In 2002, Merz established its initial production footprint in the BioPharmaPark in Dessau to manufacture the active pharmaceutical ingredient (API) botulinum neurotoxin. Merz soon invested in a state-of-the-art aseptic plant at the Dessau site for the production of its own botulinum neurotoxin, used for the treatment of neurological movement disorders and medical aesthetics. The company produces the active ingredient in a complex biotechnological process using aseptic filling and freeze-drying.